IBEX Limited
IBEX Limited Fundamental Analysis
IBEX Limited (IBEX) shows moderate financial fundamentals with a PE ratio of 8.98, profit margin of 7.35%, and ROE of 31.85%. The company generates $0.6B in annual revenue with moderate year-over-year growth of 9.77%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 63.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze IBEX's fundamental strength across five key dimensions:
Efficiency Score
ExcellentIBEX demonstrates superior asset utilization.
Valuation Score
ExcellentIBEX trades at attractive valuation levels.
Growth Score
ExcellentIBEX delivers strong and consistent growth momentum.
Financial Health Score
ExcellentIBEX maintains a strong and stable balance sheet.
Profitability Score
ModerateIBEX maintains healthy but balanced margins.
Key Financial Metrics
Is IBEX Expensive or Cheap?
P/E Ratio
IBEX trades at 8.98 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, IBEX's PEG of 0.90 indicates potential undervaluation.
Price to Book
The market values IBEX Limited at 2.58 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 4.82 times EBITDA. This is generally considered low.
How Well Does IBEX Make Money?
Net Profit Margin
For every $100 in sales, IBEX Limited keeps $7.35 as profit after all expenses.
Operating Margin
Core operations generate 9.05 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $31.85 in profit for every $100 of shareholder equity.
ROA
IBEX Limited generates $14.98 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
IBEX Limited generates limited operating cash flow of $59.07M, signaling weaker underlying cash strength.
Free Cash Flow
IBEX Limited produces free cash flow of $29.28M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $2.17 in free cash annually.
FCF Yield
IBEX converts 7.37% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
8.98
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.90
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.58
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.66
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.42
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.83
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.32
vs 25 benchmark
ROA
Return on assets percentage
0.15
vs 25 benchmark
ROCE
Return on capital employed
0.26
vs 25 benchmark
How IBEX Stacks Against Its Sector Peers
| Metric | IBEX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 8.98 | 35.19 | Better (Cheaper) |
| ROE | 31.85% | 1155.00% | Weak |
| Net Margin | 7.35% | -127067.00% (disorted) | Weak |
| Debt/Equity | 0.42 | 0.41 | Neutral |
| Current Ratio | 1.83 | 4.71 | Neutral |
| ROA | 14.98% | -314918.00% (disorted) | Strong |
IBEX outperforms its industry in 2 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews IBEX Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
66.08%
Industry Style: Growth, Innovation, High Beta
High GrowthEPS CAGR
471.82%
Industry Style: Growth, Innovation, High Beta
High GrowthFCF CAGR
6.42%
Industry Style: Growth, Innovation, High Beta
Growing